Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.72 |
| ▸ | KCNH2 known ✓ | Q12809 | 2/20 | 0.72 |
| ▸ | HRH2 known ✓ | P25021 | 1/20 | 0.72 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.52 |
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.52 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.52 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.52 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.43 |
| ▸ | ADRB2 known ✓ | P07550 | 3/20 | 0.40 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.74 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.74 |
| ▸ | TSHR | P16473 | 1/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.72 |
| ▸ | LMNA | P02545 | 2/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.72 |
| ▸ | GBA1 | P04062 | 1/20 | 0.72 |
| ▸ | CNR1 | P21554 | 1/20 | 0.72 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29729337 | 1.00 | CYP3A4 (0.74) | CYP3A4TDP1ALOX15TSHRCYP2D6 | |
| SCHEMBL24446594 | 0.98 | CYP2D6 (0.74) | CYP3A4TDP1ALOX15TSHRCYP2D6 | |
| SCHEMBL30080216 | 0.98 | CYP2D6 (0.74) | CYP3A4TDP1ALOX15TSHRCYP2D6 | |
| SCHEMBL2342350 | 0.98 | CYP2D6 (0.74) | CYP3A4TDP1ALOX15TSHRCYP2D6 | |
| SCHEMBL24446500 | 0.89 | CYP2D6 (0.65) | CYP3A4TDP1ALOX15TSHRCYP2D6 | |
| SCHEMBL22927420 | 0.89 | CYP2D6 (0.65) | CYP3A4TDP1ALOX15TSHRCYP2D6 | |
| SCHEMBL24446428 | 0.88 | CYP2D6 (0.67) | CYP3A4TDP1ALOX15TSHRCYP2D6 | |
| SCHEMBL22927156 | 0.87 | CYP2D6 (0.67) | CYP3A4TDP1ALOX15TSHRCYP2D6 | |
| Hydrochloric Acid SCHEMBL10808670 | 0.87 | CYP3A4 (0.77) | CYP3A4TDP1ALOX15TSHRCYP2D6 | |
| Hydrochloric Acid SCHEMBL10808667 | 0.87 | CYP3A4 (0.77) | CYP3A4TDP1ALOX15TSHRCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2875359-A2 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING METABOLIC SYNDROME DISORDERS | Charles R Drew University of Medicine and Science (US) | 2015-05-27 | — | — | EP | claimed |
| CN-104356002-A | Preparation process of impurities contained in expectorant drug bromhexine hydrochloride | UNIV HEBEI MEDICAL | 2015-02-18 | — | — | CN | claimed |
| EP-2670404-A1 | SIRTUIN MODULATORS AS VIRUS PRODUCTION MODULATORS | The Trustees of Princeton University (US) | 2013-12-11 | — | — | EP | claimed |
| WO-2013149258-A2 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING METABOLIC SYNDROME DISORDERS | Charles Drew University of Medicine and Science (US) | 2013-10-03 | — | — | WO | claimed |
| WO-2012106509-A1 | SIRTUIN MODULATORS AS VIRUS PRODUCTION MODULATORS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2012-08-09 | — | — | WO | claimed |
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | ALUME BIOSCIENCES, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| EP-4484952-A2 | OPTIMIZED PEPTIDES FOR TARGETING HUMAN NERVES AND THEIR USE IN IMAGE GUIDED SURGERY, DIAGNOSTICS AND THERAPEUTIC DELIVERY | The Regents of the University of California (US) | 2025-01-01 | — | — | EP | disclosed |
| US-20240358634-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-10-31 | — | — | US | disclosed |
| EP-3661539-B1 | OPTIMIZED PEPTIDES FOR TARGETING HUMAN NERVES AND THEIR USE IN IMAGE GUIDED SURGERY, DIAGNOSTICS AND THERAPEUTIC DELIVERY | UNIV CALIFORNIA (US) | 2024-10-09 | — | — | EP | disclosed |
| US-20240207421-A1 | NERVE TARGETING PEPTIDES AND METHODS OF USE | ALUME BIOSCIENCES INC (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240207422-A1 | NERVE TARGETING PEPTIDE CONJUGATES AND METHODS OF USE | ALUME BIOSCIENCES INC (US) | 2024-06-27 | — | — | US | disclosed |
| US-11969501-B2 | Auris formulations for treating otic diseases and conditions | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-04-30 | — | — | US | disclosed |
| US-20060111435-A1 | Contacting cells with sirtuin activator or inhibitor; increasing or decreasing fat accumulation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2006-05-25 | — | — | US | disclosed |
| US-20060084085-A1 | Methods and compositions for modulating Bax-mediated apoptosis | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2006-04-20 | — | — | US | disclosed |
| WO-2006007411-A2 | METHODS AND COMPOSITIONS FOR MODULATING BAX-MEDIATED APOPTOSIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2006-01-19 | — | — | WO | disclosed |
| WO-2005065667-A2 | COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2005-07-21 | — | — | WO | disclosed |
| US-20040219207-A1 | Drug preparation comprising alpha-lipoic acid, ambroxol and/or inhibitors of the angiotensin-converting enzyme (ACE) and its use for the treatment of neurodegenerative diseases | KEYNEUROTEK PHARMACEUTICALS AG (DE) | 2004-11-04 | — | — | US | disclosed |
| EP-1442743-A1 | Medicament comprising alpha-lipoic acid, ambroxol and/or inhibitors of the angiotensin converting enzyme (ACE) for use in the treatment of neurodegenerative diseases | KeyNeurotek AG (DE) | 2004-08-04 | — | — | EP | disclosed |
| US-20040138311-A1 | Medicament containing an effector of the glutathione metabolism together with $g(a)-lipoic acid for treating diabetes mellitus | ESPARMA GMBH (DE) | 2004-07-15 | — | — | US | disclosed |
| US-20040127550-A1 | Medicament containing an effector of the glutathione metabolism together with alpha-lipoic acid for use in kidney replacement therapy | SERUMWERK BERNBURG AG (DE) | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111435-A1 | Contacting cells with sirtuin activator or inhibitor; increasing or decreasing fat accumulation | FABP4, PLIN1, SIRT1 | SLC6A4 4637/4885KCNH2 4828/4885HRH2 4813/4885 |
| US-20040219207-A1 | Drug preparation comprising alpha-lipoic acid, ambroxol and/or inhibitors of the angiotensin-converting enzyme (ACE) and its use for the treatment of neurodegenerative diseases | ACE, LCT, CTSA | SLC6A4 3525/4885KCNH2 4446/4885HRH2 164/4885 |
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | NGLY1, VGF, GAP43 | SLC6A4 3444/4885KCNH2 2148/4885HRH2 1524/4885 |
| US-20240358634-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | SLC6A4 867/4885KCNH2 2334/4885HRH2 269/4885 |
| US-20060084085-A1 | Methods and compositions for modulating Bax-mediated apoptosis | BAX, BCL2, CASP3 | SLC6A4 4844/4885KCNH2 4677/4885HRH2 4689/4885 |
| US-20040138311-A1 | Medicament containing an effector of the glutathione metabolism together with $g(a)-lipoic acid for treating diabetes mellitus | GSR, GLS, MGST3 | SLC6A4 1732/4885KCNH2 4861/4885HRH2 2795/4885 |
| US-11969501-B2 | Auris formulations for treating otic diseases and conditions | OTC, AQP4, SLC26A4 | SLC6A4 867/4885KCNH2 2334/4885HRH2 269/4885 |
| US-20040127550-A1 | Medicament containing an effector of the glutathione metabolism together with alpha-lipoic acid for use in kidney replacement therapy | GLS, GSTA1, GSTK1 | SLC6A4 2878/4885KCNH2 4702/4885HRH2 2254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.